-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US98973P1012 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 5M |
|---|---|
| Beta | -1.08 |
| PE Ratio | None |
| Target Price | 1.75 |
| Dividend Yield | None |
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TCRT using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025